Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.42 |
| ▸ | RELA | Q04206 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7298660 | 0.84 | APP (0.42) | APPRAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL7301025 | 0.78 | CYP1A2 (0.48) | APPRAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL19783341 | 0.76 | KMT2A (0.36) | APPRAB9ASMN1; SMN2POLBTP53 | |
| SCHEMBL2138067 | 0.75 | APP (0.49) | APPRAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL30903623 | 0.75 | APP (0.45) | APPRAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL27925517 | 0.75 | APP (0.45) | APPRAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL543524 | 0.75 | HSD17B10 (0.44) | RAB9ASMN1; SMN2LMNATP53HSD17B10 | |
| SCHEMBL8975809 | 0.75 | PDE10A (0.31) | RAB9ASMN1; SMN2POLBNPC1MAPT | |
| SCHEMBL30594904 | 0.74 | APP (0.49) | APPRAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL5116616 | 0.74 | SMN1; SMN2 (0.51) | APPRAB9ASMN1; SMN2LMNANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2959918-B1 | ANTI-MALIGNANT TUMOR AGENT COMPOSITION | J PHARMA CO LTD (JP) | 2019-05-22 | — | — | EP | disclosed |
| US-10172835-B2 | Anticancer agent composition | J-PHARMA CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20160279103-A1 | AN ANTICANCER AGENT COMPOSITION | J-PHARMA CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| CN-105392498-A | Anti-malignant tumor agent composition | PHARMA CO LTD J | 2016-03-09 | — | — | CN | disclosed |
| EP-2959918-A1 | ANTI-MALIGNANT TUMOR AGENT COMPOSITION | J-Pharma Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-1481965-B1 | AROMATIC AMINO ACID DERIVATIVES AND MEDICINAL COMPOSITIONS | ENDO HITOSHI (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-7345068-B2 | Aromatic amino acid derivatives and medicinal compositions | Endou, Hitoshi (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20050119256-A1 | Aromatic amino acid derivates and medicinal compositions | HITOSHI ENDOU (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1481965-A1 | AROMATIC AMINO ACID DERIVATIVES AND MEDICINAL COMPOSITIONS | Endo, Hitoshi (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-5412099-A | Intermediate benzothiazolyl- and benzoxazolyl-aldehyde compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-02 | — | — | US | disclosed |
| EP-0450420-B1 | Dihydropyridines substituted by heterocycles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1994-09-21 | — | — | EP | disclosed |
| US-5254692-A | Inotropic | BAYER AKTIENGESELLSCHAFT (DE) | 1993-10-19 | — | — | US | disclosed |
| US-5200420-A | Inotropic agents for cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-06 | — | — | US | disclosed |
| EP-0450420-A2 | Dihydropyridines substituted by heterocycles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279103-A1 | AN ANTICANCER AGENT COMPOSITION | TUBB1, TUBA1A, TUBA1C | APP 4263/4885RAB9A 2226/4885SMN1; SMN2 1404/4885 |
| US-20050119256-A1 | Aromatic amino acid derivates and medicinal compositions | SLC7A1, SLC1A5, SLC7A5 | APP 3226/4885RAB9A 1260/4885SMN1; SMN2 4118/4885 |
| US-10172835-B2 | Anticancer agent composition | TOP1, TUBB1, TUBA1A | APP 4282/4885RAB9A 1986/4885SMN1; SMN2 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.